View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 15, 2020

Lilly plans to seek EUA for baricitinib to treat Covid-19 patients

Eli Lilly has plans to discuss with the US Food and Drug Administration (FDA) and other regulatory agencies, the potential for emergency use authorisation (EUA) of its rheumatoid arthritis drug baricitinib to treat hospitalised Covid-19 patients.

Eli Lilly has plans to discuss with the US Food and Drug Administration (FDA) and other regulatory agencies, the potential for emergency use authorisation (EUA) of its rheumatoid arthritis drug baricitinib to treat hospitalised Covid-19 patients.

The decision comes from data of ACTT-2 clinical trial, where researchers compared the combination of 4mg baricitinib plus Gilead Sciences’ remdesivir to remdesivir alone in more than 1,000 hospitalised patients.

According to the trial findings, the combination met the primary endpoint of reduction of time to recovery versus remdesivir. Around one-day decrease in median recovery time was observed in the overall patient population on the combination therapy.

Recovery was determined as the patient feeling well enough for hospital discharge or no longer hospitalised at day 29.

Furthermore, the trial met a key secondary endpoint of patient outcomes at day 15 using an ordinal 8-point scale ranging from fully recovered to death.

Additional analyses are in motion to capture other clinical outcome data, including mortality and safety data.

The National Institute of Allergy and Infectious Diseases (NIAID) sponsored the trial.

Eli Lilly senior vice-president and chief scientific officer Daniel Skovronsky said: “These data allow us to better understand baricitinib’s role in potentially improving outcomes for hospitalised Covid-19 patients, and we look forward to continuing this research alongside our other initiatives to combat Covid-19.”

If authorised for emergency use, Lilly will make baricitinib available via commercial channels and work with hospitals and governments to allow patient access.

The company intends to generate adequate supply for rheumatoid arthritis patients and ensure the availability of the drug in markets where it holds approval.

Baricitinib, a JAK1 / JAK2 inhibitor, is marketed as Olumiant. It has approval in more than 70 countries to treat adults with moderately to severely active rheumatoid arthritis.

Currently, Lilly is supporting ongoing investigator-initiated studies in Europe and North America for hospitalised Covid-19 patients.

Earlier this month, Lilly received approval from the FDA for two additional doses of its type 2 diabetes drug Trulicity (dulaglutide).

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU